Myosin Therapeutics AML program small molecule

This unnamed small molecule is a modulator of the myosin superfamily of molecular nanomotors, currently in preclinical development by Myosin Therapeutics for the treatment of Acute Myeloid Leukemia (AML). Myosin Therapeutics utilizes a platform focused on discovering novel small molecule modulators for the understudied myosin protein family, which plays critical roles in cellular processes such as cytokinesis, cell motility, and intracellular transport. While specific details regarding the isoform selectivity for the AML candidate have not been publicly disclosed, the company's broader pipeline targets non-muscle myosin II (NMII) isoforms to disrupt disease-specific cellular mechanics.